No Data
No Data
Top Premarket Decliners
Medicus Pharma Ltd's Promising Clinical Developments and Strategic Expansion Drive Buy Rating
Medicus Pharma Expands Basal Cell Carcinoma Study After Encouraging Early Data | NASDAQ:MDCX
Medicus Pharma Is Maintained at Buy by D. Boral Capital
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
This Millrose Properties Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday